French company inHEART, a cloud-based medical imaging solution for cardiac patients, has raised €3.7 million from Elaia and Aquitaine Science Transfert. The funds will be used to accelerate commercial development in Europe, enter the US market and continue product development in artificial intelligence.
Commenting on the new investment, CEO and co-founder Jean-Marc Peyrat said, “Elaia and inHEART share the same ambition to create a major player in cardiac electrophysiology, a €5 billion market that includes healthcare giants such as Johnson & Johnson, Abbott, Boston Scientific or Medtronic.”
The startup is a spin-off from IHU Liryc and Inria, two French research centres that specialise in cardiac electrophysiology and computer science, respectively. The team developed a solution that transforms preoperative medical images into a 3D digital twin of the patient’s heart. Thanks to AI, this digital twin displays ‘numerical simulations’ of cardiac electrical activity, which helps the cardiologist to better plan the procedure and also assists in navigating instruments in the patient’s heart.
“After more than ten years of multidisciplinary collaboration as only a few exist in the world between cardiologists, radiologists, engineers and researchers in computer science, we have a disruptive technology that answers a real clinical need,” added Professor Hubert Cochet, radiologist and co-founder of inHEART.
In a press release, the medtech company says it aims to reduce procedure time and failure rates by half. So far the software has been used with over 2,000 patients in more than 40 medical centers around the world.